Rodger Tiedemann, MD, PHD, FRACP, FRCPA

Rodger Tiedemann, MD, PHD, FRACP, FRCPA


Research Focus:
One of our research interests is to define all essential and potentially 'druggable' survival genes required by myeloma tumor cells. We are attempting to do this by conducting large-scale RNA interference genetic screens in a range of myeloma cells using pooled lentivirus libraries containing 80,000+ shRNA targeting the genome. To capture the genetic heterogeneity of myeloma tumors in our results, we are screening a panel of hypo- or hyper-diploid tumor lines bearing common t(4;14), t(11;14) or t(14;16) translocations and 13q or 17p deletions. Previously, we have used smaller scale RNA interference studies, including a 17,000 siRNA screen, to identify critical Achilles heel vulnerabilities within a portion of the genome in myeloma cells.

years treating myeloma:

Number of Myeloma Patients Treated Annually:

Details & contact info

Princess Margaret Cancer Centre

610 University Avenue Discovery District Old Toronto
Toronto, Canada, Canada, M5T 1N7

Phone: 1-866-797-0000

View Full Physician Bio

View Website

Send a message to Rodger Tiedemann, MD, PHD, FRACP, FRCPA


Thanks to our Myeloma Crowd Community sponsors:

.                         .       .